Five things to know about what could be America’s first cannabis-derived drug

If approved by the Food and Drug Administration, GW Pharmaceuticals PLC’s cannabis-derived drug, which treats child epilepsy, would be the first of its kind in the U.S.

And while FDA approval is by no means a sure thing, U.K.-based GW GWP, -10.08% announced positive phase-three trial results for the drug, Epidiolex, Monday morning, sending its shares ballooning over 130%.

Designed to treat a rare type of child epilepsy called Dravet Syndrome, Epidiolex reduced children's’ seizure frequency by almost 40% over 14 weeks of treatment, a statistically significant finding.

Here are five things to know about GW’s Epidiolex and the budding cannabis drug industry:

Epidiolex is technically legal

GW could sell Epidiolex without FDA approval, but couldn’t claim medical benefits without government penalties In the last year, the FDA has sent warning letters to companies advertising cannabis-derived products like medical drugs, including one selling cannabis for...

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.